New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations

• Published in: International journal of molecular sciences Vol. 20; no. 12; p. 3013
• Main Authors: Clemons Bankston, Page, Al-Horani, Rami A.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 20.06.2019; MDPI
• Subjects: Animals; Autoimmune diseases; Blood; Blood platelets; Bone marrow; Cinnamates - chemistry; Cinnamates - pharmacology; Cinnamates - therapeutic use; Cytokines; Drug Development; Drugs; Humans; Immunoglobulins; Infections; Kinases; Ligands; Molecular weight; Oxazines - chemistry; Oxazines - pharmacology; Oxazines - therapeutic use; Peptides; Physiology; Proteins; Pyridines - chemistry; Pyridines - pharmacology; Pyridines - therapeutic use; Receptors, Thrombopoietin - agonists; Receptors, Thrombopoietin - metabolism; Review; Rheumatoid arthritis; Signal transduction; Small Molecule Libraries - chemistry; Small Molecule Libraries - pharmacology; Small Molecule Libraries - therapeutic use; Spleen; Stem cells; Syk Kinase - antagonists & inhibitors; Syk Kinase - metabolism; Thiazoles - chemistry; Thiazoles - pharmacology; Thiazoles - therapeutic use; Thiophenes - chemistry; Thiophenes - pharmacology; Thiophenes - therapeutic use; Thrombocytopenia - drug therapy; Thrombocytopenia - metabolism; Viral infections; avatrombopag; fostamatinib; lusutrombopag

This review provides details about three small molecules that were recently approved by the FDA for the treatment of thrombocytopenia. The new treatments include lusutrombopag, avatrombopag, and fostamatinib. The first two drugs are orally active thrombopoietin receptor (TPO-R) agonists which are FD...